Skip to main content
康乐卫士 logo

康乐卫士 — Investor Relations & Filings

Ticker · 920575 ISIN · CNE1000059W8 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 537 across all filing types
Latest filing 2023-12-25 Governance Information
Country CN China
Listing Beijing Stock Exchange 920575

About 康乐卫士

https://www.klws.com/

Beijing Health Guard Biotechnology Inc. is a clinical-stage biopharmaceutical company specializing in the research, development, and commercialization of innovative recombinant human vaccines. The company leverages advanced structural biology and protein engineering platforms to create a diverse pipeline of vaccine candidates. Its primary focus includes the development of high-valent human papillomavirus (HPV) vaccines, with its trivalent and nine-valent candidates in late-stage clinical trials. Additionally, the company is advancing candidates for respiratory syncytial virus (RSV), shingles, and other infectious diseases. By utilizing recombinant protein technology, Health Guard aims to provide high-quality, affordable immunization solutions to address significant unmet medical needs. Its technical expertise encompasses antigen design, high-throughput screening, and large-scale manufacturing processes.

Recent filings

Filing Released Lang Actions
董事会提名委员会议事规则（联交所上市后适用）
Governance Information Classification · 95% confidence The document is titled as the 'Board Nomination Committee Rules' for Beijing Kangle Weishi Biotechnology Co., Ltd., detailing the composition, responsibilities, and meeting procedures of the nomination committee. It references company governance, board and senior management selection processes, and compliance with listing rules of the Hong Kong Stock Exchange and Beijing Stock Exchange. There is no financial data, no mention of financial results, no voting results, no legal proceedings, no capital changes, and no report publication announcements. The content is focused on governance structure and internal rules related to board nominations. Therefore, the document fits best under Governance Information (CGR). The document length is short (2146 characters), but it is a substantive governance document, not a mere announcement or certification.
2023-12-25 Chinese
公司章程（草案）（联交所上市后适用）
Governance Information Classification · 100% confidence The document is a detailed company charter (章程) draft for Beijing Health Guard Biotechnology Inc., specifying corporate governance, shareholder rights, board structure, share issuance, and meeting procedures. It references compliance with various securities laws and stock exchange listing rules, including the Beijing Stock Exchange and Hong Kong Stock Exchange. The content is focused on internal governance rules, shareholder meeting protocols, board and management roles, share issuance and transfer rules, and other corporate governance matters. There is no indication that this is an annual report, financial statement, earnings release, or any other financial disclosure. Instead, it is a governance document outlining the company's articles of association and internal rules. Therefore, the appropriate classification is Governance Information (CGR). The document length and detail confirm it is the actual governance document, not just an announcement or summary.
2023-12-25 Chinese
投资者关系活动记录表
Regulatory Filings Classification · 95% confidence The document is an investor relations activity record from Beijing Kanglevest Biotech Co., Ltd., detailing a series of questions and answers about the company's HPV vaccine development progress, market strategy, clinical trials, production capacity, and future plans. It is a detailed narrative of an investor relations event rather than a formal financial report or regulatory filing. There are no financial statements, audit opinions, or earnings highlights. The document is not a transcript of a conference call but a record of investor Q&A. It is not an announcement of voting results, capital changes, or management changes. It is not a brief factsheet or a presentation. The document is a detailed record of investor relations activities, which fits best under the category of Regulatory Filings (RNS) as a general regulatory announcement and investor communication that does not fit other specific categories.
2023-12-20 Chinese
第四届董事会第二十七次会议决议公告
Board/Management Information Classification · 100% confidence The document is a formal announcement of the resolutions passed at the 27th meeting of the 4th Board of Directors of Beijing Kangle Weishi Biotechnology Co., Ltd. It details the meeting date, attendance, agenda items, and voting results. The content focuses on board decisions, specifically regarding a subsidiary's bank credit application and company guarantees. There is no financial report, earnings data, or regulatory filing referenced. The document is clearly about board/management information, specifically board meeting resolutions and decisions.
2023-12-13 Chinese
第四届监事会第二十六次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolution passed at the 26th meeting of the 4th Supervisory Board of Beijing Kangle Weishi Biotechnology Co., Ltd. It details the meeting's attendance, the agenda item regarding a subsidiary's application for a bank credit facility and the company's guarantee, and the voting results. The document is an official disclosure of a board/management decision rather than a full report or financial statement. It does not contain financial data or detailed financial analysis, nor is it a regulatory filing or announcement of a report publication. The content fits best under Board/Management Information (MANG) as it relates to internal company governance and decisions made by the supervisory board.
2023-12-13 Chinese
关于子公司申请银行专项授信暨公司提供担保的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding a subsidiary applying for a bank credit facility and the parent company providing guarantees. It details the guarantee amount, terms, board approval, and financial data of the subsidiary. There is no indication of financial statements or comprehensive financial reporting. The document is a formal announcement of a financing-related guarantee arrangement, not a full capital or financing update report. However, it fits best under Capital/Financing Update (CAP) as it concerns financing activities and guarantees related to credit facilities. The document length is 2865 characters, which is consistent with an announcement rather than a full report. Therefore, the classification is CAP with high confidence.
2023-12-13 Chinese

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.